MCL Literature Feed
57 papers on mantle cell lymphoma from PubMed. Updated daily.
Rituximab maintenance after bendamustine-based therapy in MCL patients is associated with worse outcomes from SARS-CoV-2 infection, highlighting a significant infectious toxicity risk for this common regimen.
Bioinformatic analysis reveals a positive correlation between STING expression and cytolytic score in MCL, suggesting STING may be a biomarker for immune activity and a potential immunotherapy target.
This case report describes an MCL diagnosis in a patient with mucous membrane pemphigoid, where frontline acalabrutinib and rituximab resolved both conditions, suggesting a paraneoplastic link.
Italian experts established consensus diagnostic and therapeutic pathways for MCL, standardizing care while highlighting ongoing debates on MRD utility, immunotherapy sequencing, and CAR-T versus bispecifics.
This retrospective study suggests a 1-day bendamustine regimen for MCL offers comparable progression-free survival to the standard 2-day schedule but with significantly less neutropenia and adverse events.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
The novel, chemotherapy-free triplet of alisertib, ibrutinib, and rituximab demonstrates clinical activity in MCL, providing a new therapeutic strategy for likely relapsed/refractory patients.
This review outlines the clinical landscape and practical application of CAR-T and bispecific antibodies for relapsed/refractory MCL, guiding their integration into practice after targeted therapy failure.
The first approval of odronextamab, a CD20xCD3 bispecific antibody, in other lymphomas introduces a promising off-the-shelf, T-cell engaging immunotherapy for potential use in relapsed/refractory MCL.
In a small retrospective study of nine untreated aggressive MCL patients, adding a BTKi to chemoimmunotherapy achieved a 100% objective response rate with manageable toxicity, suggesting a promising frontline strategy.
This review synthesizes current data and practical considerations for CAR-T and bispecific antibodies, guiding clinical decision-making and sequencing for these T-cell engaging therapies in relapsed/refractory MCL.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
This review explores CAR-NK cells as a promising alternative to CAR-T therapy for mantle cell lymphoma, potentially offering comparable efficacy with a significantly improved safety profile and fewer severe toxicities.
For transplant-eligible MCL, substituting rituximab with obinutuzumab in chemo-immunotherapy induction and maintenance significantly improved MRD negativity, 5-year progression-free survival (83% vs 67%), and overall survival.
This commentary evaluates rituximab's evolving role in MCL, questioning its necessity in modern chemo-free regimens and its place alongside novel targeted agents.
CD20-targeted CAR-T therapy induced durable remissions (>7 years) in MCL by triggering a lasting endogenous anti-tumor immune response (epitope spreading) despite a lack of CAR-T persistence.
This case series on a rare kidney disease (ABBA) reports a paraneoplastic association with mantle cell lymphoma, highlighting a rare non-hematologic manifestation potentially responsive to B-cell directed therapy.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
The R-GEMOX (rituximab, gemcitabine, oxaliplatin) chemotherapy regimen demonstrates efficacy as a salvage option for patients with relapsed/refractory mantle cell lymphoma in a phase I/II study.
Profiling T-cell differentiation stages in MCL reveals novel immunotherapeutic targets in specific patient subsets, suggesting a biomarker-driven approach for future immune-based treatments.
This systematic analysis of MAIT cells across hematological malignancies provides foundational insights into the MCL immune microenvironment, potentially identifying novel biomarkers or immunotherapy targets.
This review provides a framework for integrating bispecific antibodies into MCL treatment, addressing the critical clinical question of how to sequence them with other novel immunotherapies like CAR-T.
Long-term follow-up confirms rituximab maintenance post-transplant significantly improves overall survival in young, fit MCL patients, establishing this as a standard of care in the frontline setting.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
In elderly MCL, rituximab maintenance benefits even MRD-negative patients post-induction, arguing against de-escalation and identifying MRD-positivity as a high-risk feature needing better consolidation.
PLSCR1 induction by retinoic acid/interferon-α enhances immunogenic cell death in MCL, improving the efficacy of dendritic cell-based vaccines by boosting anti-tumor T-cell responses in vitro.
This Phase 1 study establishes the safety and recommended dose of a quadruplet regimen combining chemoimmunotherapy (BR) with dual targeted agents (ibrutinib, venetoclax) for relapsed/refractory MCL.
An MCL patient with B-cell depletion had persistent COVID-19 for over 112 days, diagnosed via lower respiratory sampling, highlighting a unique vulnerability and successful treatment with convalescent plasma.
This review explores targeting tumor-associated macrophages within the MCL microenvironment as a novel immunotherapeutic strategy to enhance anti-tumor activity and potentially overcome drug resistance.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
This case report details an extremely rare MCL presentation of bilateral hemorrhagic hypopyon, successfully treated with intravitreal rituximab, systemic chemotherapy, and radiation, expanding the differential for unusual ocular findings.
This phase 1 study established the safety and preliminary efficacy of a novel bortezomib, cladribine, and rituximab regimen for older, newly diagnosed mantle cell lymphoma patients.